Skip to main content
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc. — Investor Relations & Filings

Ticker · 4598 ISIN · JP3549370009 T Professional, scientific and technical activities
Open in API
Filings indexed 63 across all filing types
Latest filing 2024-10-07 Major Shareholding Noti…
Country JP Japan
Listing T 4598

About Delta-Fly Pharma, Inc.

https://www.delta-flypharma.co.jp/en/

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer drugs. The company's core strategy is its proprietary "Module Drug Development" concept, an approach that combines existing pharmaceutical components to create novel therapeutic agents. This methodology aims to develop effective cancer treatments with significantly reduced side effects and at reasonable prices, thereby improving the quality of life for patients. The company's pipeline includes several drug candidates for various cancers, with some, such as DFP-10917 for refractory/relapsed acute myeloid leukemia, advancing to late-stage clinical trials. Delta-Fly Pharma focuses on creating gentle yet potent therapies, including nucleoside analogs and RNA therapeutics.

Recent filings

Filing Released Lang Actions
臨時報告書
Major Shareholding Notification Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report/Timely Disclosure Report) and is submitted to the '四国財務局長' (Shikoku Local Finance Bureau Director). The filing reason explicitly states it is submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 4 of the Cabinet Office Ordinance on Disclosure of Corporate Information, due to a change in a major shareholder ('主要株主に異動がありました'). The content details the change in ownership percentage and shares held by the major shareholder, Mr. Kiyoshi Ejima, effective October 7, 2024. This structure and content strongly indicate a filing related to changes in major shareholdings, which corresponds to the Major Shareholding Notification (MRQ) definition, although the Japanese filing type is often a specific form of timely disclosure. Given the provided definitions, 'MRQ' (Major Shareholding Notification) is the most appropriate fit for reporting changes in significant share ownership thresholds.
2024-10-07 Japanese
有価証券届出書（組込方式）
Capital/Financing Update Classification · 99% confidence The document is titled '有価証券届出書' (Securities Registration Statement) on the cover page and is submitted to the '四国財務局長' (Director of Shikoku Local Finance Bureau) on '2024年９月20日'. It details the offering of '新株予約権証券' (Stock Acquisition Rights Certificates) for the 8th and 9th series, including issuance terms, exercise prices, and intended use of proceeds. This structure and content strongly indicate a filing related to the issuance of new securities, which falls under the category of Capital/Financing Update (CAP) in the provided definitions, as it is a formal registration document for raising capital via stock acquisition rights. It is not a general earnings release (ER), an annual report (10-K), or a simple announcement (RPA/RNS), but a comprehensive registration for a capital event.
2024-09-20 Japanese
臨時報告書
Major Shareholding Notification Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) in the header and explicitly states in Section 1 ('提出理由') that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 4 of the Cabinet Office Ordinance on Disclosure of Corporate Information, due to a change in a major shareholder. This structure and legal basis strongly indicate a Japanese regulatory filing concerning a change in major shareholding. The content details the change in voting rights percentage and share count for a major shareholder ('江島 淸'). This aligns perfectly with the definition of 'Major Shareholding Notification' (Code: MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Although it is a regulatory filing, MRQ is the most specific category available.
2024-09-11 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) in the header and explicitly states in Section 1 ('提出理由') that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, following resolutions made at the Annual General Meeting (AGM) held on June 27, 2024. Section 2 ('報告内容') details the resolutions passed, specifically the election of directors and a provisional auditor, along with the voting results (votes for, against, abstentions). This content perfectly matches the definition of reporting the results of a shareholder vote, which corresponds to the Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to an AGM, the primary focus is reporting the *results* of the vote, not the presentation materials (AGM-R) or the proxy solicitation (DEF 14A/PSI).
2024-06-28 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (614 characters) and contains a header section typical of Japanese regulatory filings, specifically mentioning '【提出書類】確認書' (Filing Document: Confirmation Document) and referencing the Financial Instruments and Exchange Act ('金融商品取引法'). The core content confirms the appropriateness of the contents of the company's 14th period Annual Securities Report ('有価証券報告書') for the period ending March 31, 2024, signed by the CEO and CFO. This document is a formal certification or confirmation related to the Annual Report (10-K equivalent in Japan, called 'Yuka Shoken Hokokusho'). Since it is a confirmation document *about* the Annual Report, and not the full report itself, it is best classified as a general Regulatory Filing (RNS) or potentially an Audit Report/Information (AR) if it were a formal audit sign-off, but given the context of confirming the *contents* of the 10-K, RNS is the most appropriate general regulatory category for this specific certification document, as it doesn't fit the specific definitions of 10-K, AR, or ER. Given the options, RNS (Regulatory Filings) serves as the best fit for miscellaneous, specific regulatory confirmations that aren't the primary report. FY 2024
2024-06-28 Japanese
内部統制報告書－第14期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document explicitly states the filing type in the header section: "【提出書類】 内部統制報告書" (Filing Document: Internal Control Report). It also cites the legal basis: "【根拠条文】 金融商品取引法第24条の４の４第１項" (Legal Basis: Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). This type of report, focusing on the assessment of internal controls over financial reporting, corresponds to the Audit Report / Information category (AR) in the provided definitions, as it deals with internal controls and assurance standards, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER). The content confirms this by discussing the framework, scope, and conclusion regarding internal controls.
2024-06-28 Japanese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.